Bone and paraproteinemias.
OBJECTIVE
Bone has always been considered a target organ for neoplastic disorder. This review analyzed the close interaction between bone microenvironment and paraproteinemias.


RESULTS
Paraproteinemias are a group of disorders characterized by the presence of a monoclonal protein measured in the blood or urine. Paraproteinemias include nonmalignant B cell disorders such as monoclonal gammopathy of undetermined significance and malignant diseases as multiple myeloma. All these conditions are characterized by increased risk of osteoporosis/osteopenia, and in the setting of multiple myeloma can manifest with osteolytic pattern.


CONCLUSIONS
This review focuses on the biological aspects of paraproteinemia and bone disease, and indicates possible new therapeutic interventions.
Zangari
Maurizio
M
University of Utah School of Medicine, Salt Lake City, Utah 84132, USA. maurizio.zangiri@hsc.utah.edu
Zhan
Fenghuang
F
Tricot
Guido
G
D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology*; D001842:Bone and Bones / Q000378:metabolism / Q000503:physiopathology*; D004164:Diphosphonates / Q000627:therapeutic use; D006801:Humans; D009101:Multiple Myeloma / Q000378:metabolism / Q000503:physiopathology; D010265:Paraproteinemias / Q000378:metabolism / Q000503:physiopathology*; D011379:Prognosis; D012307:Risk Factors
D050071:Bone Density Conservation Agents; D004164:Diphosphonates